6304-16-1

Basic information

• Product Name: 4-Pyridyl acetone
• Synonyms: 1-(4-Pyridyl)-2-propanone;4-Pyridinolacetone;(4-Pyridyl)acetone,98%;1-(4-Pyridinyl)-2-propanone CAS:;(4-PYRIDINEYL)-ACETONE;1-(4-Pyridyl)-2-acetone;4-ACETONYLPYRIDINE;Einecs 228-605-7
• CAS NO: 6304-16-1
• Molecular Formula: C₈H₉NO
• Molecular Weight: 135.16
• EINECS: 228-605-7
• Product Categories: Pyridines
• Mol File: 6304-16-1.mol

Chemical Properties

• Melting Point: 13°C
• Boiling Point: 143°C 20mm
• Flash Point: 143°C/20mm
• Appearance: /
• Density: 1.046 g/cm³
• Vapor Pressure: 0.059mmHg at 25°C
• Refractive Index: 1.5225
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 4.90±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• BRN: 110960
• CAS DataBase Reference: 4-Pyridyl acetone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridyl acetone(6304-16-1)
• EPA Substance Registry System: 4-Pyridyl acetone(6304-16-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37
• Hazardous Substances Data: 6304-16-1(Hazardous Substances Data)

Usage

Preparation

4-Pyridyl acetone can be prepared by reacting with 4-picoline and phenyllithium and ethyl acetate.

Synthesis Reference(s)

Tetrahedron Letters, 25, p. 3297, 1984 DOI: 10.1016/S0040-4039(01)81368-X

InChI:InChI=1/C8H9NO/c1-7(10)6-8-2-4-9-5-3-8/h2-5H,6H2,1H3

Upstream product

• 108-89-4 picoline 
• 591-51-5 phenyllithium 
• 111500-00-6 [1-(2,4-dichloro-benzyl)-1H-[4]pyridyliden]-acetone 
• 138-89-6 p-dimethylaminonitrosobenzene 
• 111500-01-7 [1-(2,6-dichloro-benzyl)-1H-[4]pyridyliden]-acetone 
• 506-96-7 Acetyl bromide 
• 26954-25-6 (4-pyridylmethyl)lithium 
• 79-20-9 acetic acid methyl ester 
• 141-78-6 ethyl acetate 
• 1003-67-4 4-methylpyridine-1-oxide 
• 108-24-7 acetic anhydride 
• 6622-91-9 2-(pyridine-4-yl)acetic acid hydrochloride 
• 93617-62-0 4-(2-Oxo-propyl)-4H-pyridine-1-carboxylic acid phenyl ester 
• 76639-06-0 2,6-Dimethyl-4'-(2-oxo-propyl)-4'H-[1,1']bipyridinyl-4-one 

Downstream Products

• 78415-72-2 1,6-dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile 
• 143778-88-5 6-methyl-4-(m-nitrophenyl)-3-cyano-5-(4'-pyridyl)pyridin-2(1H)-one 
• 143755-38-8 6-hydroxy-6-methyl-4-(m-nitrophenyl)-3-cyano-5-(4'-pyridyl)-3,4,5,6-tetrahydropyridin-2(1H)-one 
• 143755-40-2 6-methyl-4-(m-nitrophenyl)-3-carbamoyl-5-(4'-pyridyl)-3,4-dihydropyridin-2(1H)-one 
• 78504-61-7 1-(4-pyridinyl)-2-(dimethylamino)ethenyl methyl ketone 
• 88349-61-5 (Z)-4-ethoxy-3-(pyridin-4-yl)but-3-en-2-one 
• 101712-27-0 4-Nitro-2-pyridin-4-yl-phenol 
• 353525-92-5 methyl(1-methyl-2-(4-pyridyl)ethyl)amine 
• 80047-24-1 1,6-dihydro-2-methyl-6-oxo-<3,4'-bipyridine>-5-carboxamide 
• 143755-47-9 2-carbamoylmethylthio-6-methyl-4-(m-nitrophenyl)-3-cyano-5-(4'-pyridyl)pyridine 
• 746575-75-7 2-cyanomethylthio-6-methyl-4-(m-nitrophenyl)-3-cyano-5-(4'-pyridyl)-1,4-dihydropyridine 
• 143755-44-6 2-carbamoylmethylthio-6-methyl-4-(m-nitrophenyl)-3-cyano-5-(4'-pyridyl)-1,4-dihydropyridine 
• 365532-56-5 4-Amino-2-pyridin-4-yl-phenol 
• 80047-30-9 2-Methyl-6-oxo-1,6-dihydro-3,4'-bipyridyl 

Relevant articles and documents

Discovery of potent and selective CDK8 inhibitors through FBDD approach

A fragment library screen was carried out to identify starting points for novel CDK8 inhibitors. Optimization of a fragment hit guided by co-crystal structures led to identification of a novel series of potent CDK8 inhibitors which are highly ligand efficient, kinase selective and cellular active. Compound 16 was progressed to a mouse pharmacokinetic study and showed good oral bioavailability.

Chemoenzymatic Asymmetric Synthesis of Pyridine-Based α-Fluorinated Secondary Alcohols

Fluoro-substituted and heteroaromatic compounds are valuable intermediates for a variety of applications in pharma- and agrochemistry and synthetic chemistry. This study investigates the chemoenzymatic preparation of chiral alcohols bearing a heteroaromatic ring with an increasing degree of fluorination in α-position. Starting from readily available picoline derivatives prochiral α-halogenated acyl moieties were introduced with excellent selectivity and 64–95 % yield. The formed carbonyl group was subsequently reduced to the corresponding alcohols using the alcohol dehydrogenase from Lactobacillus kefir, yielding an enantiomeric excess of 95–>99 % and up to 98 % yield.

Aldehyde to Ketone Homologation Enabled by Improved Access to Thioalkyl Phosphonium Salts

Phosphines were previously unusable as Pummerer-type nucleophiles due to competing redox chemistry with sulfoxides. Here we circumvent this problem to achieve a formal phosphine Pummerer reaction that offers thioalkyl phosphonium salts that, in turn, give rise to diverse vinyl sulfides via Wittig olefinations. Thirty vinyl sulfides are thus prepared from (alkylthioalkyl)triphenyl phosphonium salts and aldehydes. The hydrolysis of these vinyl sulfides offers an efficient and versatile two-step one-carbon homologation of aldehydes to ketones.

Preparation method of medical intermediate milrinone

The invention discloses a preparation method of a medical intermediate milrinone. The preparation method comprises the following steps: S1, sequentially adding 4-methylpyridine and acetic anhydride into a reaction bottle, dropwise adding concentrated sulfuric acid, stirring and reacting for 20-30 minutes, continuing reaction at 40-60 DEG C, completely reacting by TLC (Thin Layer Chromatography), cooling in an ice bath, dropwise adding ethanol, stirring for 1 hour, heating and refluxing for 6-8 hours, extracting dichloromethane, drying, filtering, carrying out rotary evaporation on filtrate toremove a solvent dichloromethane, distilling out 4-methylpyridine by reduced pressure distillation, cooling, and carrying out reduced pressure distillation to obtain 1-(4-pyridyl)-acetone; S2, mixing1-(4-pyridyl)-acetone, triethyl orthoformate, glacial acetic acid and acetic anhydride, adding alpha-cyanoacetamide, and performing cyclization under the alkaline condition to obtain crude milrinone;and S3, adding DMF into the crude milrinone obtained in the S2, stirring until the solid is dissolved, adding a decolorizing agent, stirring and refluxing for 8-20 minutes, filtering, and cooling thefiltrate to separate out refined milrinone. According to the method, the raw material cost is saved, and the product purity, yield and color degree are improved.

A high-purity process for preparing milrinone

The invention discloses a preparation method for high-purity milrinone (shown as a formula (I), 1,6-dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile), and belongs to the field of chemical medicines. The method comprises: employing 4-methylpyridine as a raw material and acetylating with acetyl chloride, and hydrolyzing after the reaction is finished, so as to obtain a compound of a formula (III); mixing the compound of the formula (III) with glacial acetic acid, acetic anhydride and triethyl orthoformate, and reacting at 35 DEG C-45 DEG C, so as to obtain a compound of a formula (IV); performing cyclization on the compound of the formula (IV) and alpha-cyanoacetamide, so as to obtain a crude product of a compound of the formula (I); and refining the crude product of the formula (I) compound through an ethanol-water system, so as to obtain a high-purity refined product with the maximum interplanar spacing d of 8.39 +/- 0.02 Angstrom. The technology is relatively mild in reaction conditions and relatively simple in operation, and is capable of preparing the milrinone product with high purity and a single crystal form. The obtained milrinone crystal form is relatively excellent in solubility in normal saline or glucose, and is beneficial for improvement of the preparation quality.

The method of manufacturing the amine compound Bicylic

PROBLEM TO BE SOLVED: To provide a method for simply obtaining a bicyclic amine compound at high yield and for suppressing by-product tar contents that may obstruct the continuous production. SOLUTION: The compound indicated by a formula (1) is subjected to intramolecular dehydration in a gas phase under the presence of a solid catalyst to produce the bicyclic amine compound indicated by a formula (2). In the formula (1), R1-R8each independently represents a hydrogen atom, a 1-4C alkyl group, a hydroxy group, a hydroxymethyl group or a 1-4C alkoxy group; X represents a carbon atom or a nitrogen atom; and Y represents a hydrogen atom, an alkyl group, a hydroxy group or a 1-4C hydroxyalkyl group. In the formula (2), R1-R8, X and Y are defined in the same manner as above. COPYRIGHT: (C)2012,JPOandINPIT

Method for preparing milrinone

The invention provides a method for preparing milrinone, wherein the method comprises the following steps: with 4-methyl pyridine (SM) as a raw material, in ethyl acetate, generating 1-(4-pyridyl)-2-acetone (represented by the formula I); then under action of triethyl orthoformate, acetic acid and acetic anhydride, generating 1-ethoxy-2-(4-pyridyl)vinyl methyl ketone (represented by the formula II); and finally, under an alkaline condition, carrying out a reaction of 1-ethoxy-2-(4-pyridyl)vinyl methyl ketone with cyanoacetamide to generate milrinone. The method has the advantages of simple and efficient operation, mild reaction conditions, strong safety, easy control and relatively high yield, and is suitable for industrialized production.

Preparation method of milrinone

A preparation method of milrinone comprises the following steps: reacting n-butyl lithium with 4-methyl pyridine to generate pyridine methyl lithium, then reacting pyridine methyl lithium with propyl acetate to generate 1-(4-pyridyl)-acetone; reacting 1-(4-pyridyl)-acetone with tripropyl orthoformate and acetic anhydride to generate 1-propoxyl-2-(4-pyridyl)-vinyl methyl ketone; finally reacting 1-propoxyl-2-(4-pyridyl)-vinyl methyl ketone with cyanoacetamide in the presence of sodium ethoxide taken as the alkalizer, adding the reaction product into a mixed solution of dimethyl formamide and water, and carrying out recrystallization. The preparation method has the advantages that the yield of milrinone is prominently improved, the product purity is increased, and the color and crystal form of product are both improved.

Small molecule that reverses dexamethasone resistance in t-cell acute lymphoblastic leukemia (T-ALL)

Glucocorticoids are one of the most utilized and effective therapies in treating T-cell acute lymphoblastic leukemia. However, patients often develop resistance to glucocorticoids, rendering these therapies ineffective. We screened 9517 compounds, selected for their lead-like properties, chosen from among 3372615 compounds, against a dexamethasone-resistant T-ALL cell line to identify small molecules that reverse glucocorticoid resistance. We synthesized analogues of the most effective compound, termed J9, from the screen in order to define the scaffolds structure-activity relationship. Active compounds restored sensitivity to glucocorticoids through upregulation of the glucocorticoid receptor. This compound and mechanism may provide a strategy for overcoming glucocorticoid resistance in patients with T-ALL.

PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.